texas oncology more breakthroughs. more victories
  • Request an Appointment
  • Find a cancer center
  • Find a provider
  • Clinical Trials



Morris D. Groves, M.D.

General Summary

Morris D. Groves, M.D., leads the Texas Oncology–Austin Brain Tumor Center. Dr. Groves develops novel clinical trials using promising new treatments to help patients fight brain tumors.

Prior to joining Texas Oncology, Dr. Groves served as both a tenured associate professor for the department of neuro-oncology and as associate director for the Brain and Spine Center at The University of Texas MD Anderson Cancer Center in Houston. He has served as principal investigator and co-principal investigator on dozens of important research trials and has held many academic appointments during his tenure with The University of Texas MD Anderson Cancer Center. In addition, he has authored numerous research papers and articles on brain cancer.


Dr. Groves received his medical degree in 1986 from Baylor College of Medicine in Houston. He completed his residency training in neurology in 1996 and served as chief resident in neurology at The University of Texas Health Science Center at Houston. Dr. Groves completed his fellowship in neuro-oncology at The University of Texas MD Anderson Cancer Center in 1998. In addition, he earned a law degree in 1991 from South Texas College of Law in Houston.

Medical Practice

Other Information

Accolades & Memberships

Dr. Groves received The Gullikson Foundation Award for Quality of Life Research in 2000 and has been recognized as one of the Best Doctors in America consecutively since 2005. Dr. Groves is a member of the American Society of Clinical Oncology, American Association for Cancer Research, and the Society for Neuro-Oncology.

Community Service

Research Interest

Research interests are related to CNS tumors and include: testing of novel targeted, immunological and combination therapies, developing unique clinical trial designs, circulating biomarkers and the genetics underlying CNS tumor development.


  • Leptomeningeal Metastases: A RANO Proposal for Response Criteria

    Neuro-Oncology, 2017

  • Leptomeningeal metastases presenting exclusively with ocular disturbance in 34 patients: A tertiary care cancer hospital experience

    Journal of Clinical Neuroscience, 2017

  • Most common sites on MRI of intracranial neoplastic leptomeningeal disease

    Journal of Clinical Neuroscience, 2017

  • Association between 18F-FDG PET/CT and MRI appearance of spinal leptomeningeal disease before and after treatment at a tertiary referral center

    Journal of Solid Tumors, 2016

  • Brain Tumor Trials Collaborative. A Phase II study of Bevacizumab and Erlotinib after Radiation and Temozolomide in MGMT unmethylated GBM patients

    Journal of Neuro-Oncology, 2016

Show all Publications
  • Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma

    Neuro-Oncology, 2015

  • A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study

    Neuro-Oncology, 2015

  • Phase I/II Study of Erlotinib and Temsirolimus for Patients with Recurrent Malignant Glioma: North American Brain Tumor Consortium Trial 04-02

    Neuro-Oncology, 2014

  • A Phase I/II Trial of Pazopanib in Combination with Lapatinib in Adult Patients with Relapsed Malignant Glioma

    Clinical Cancer Research, 2013

  • Leptomeningeal metastases from genitourinary cancer: The University of Texas MD Anderson Cancer Center experience

    Medical Oncology, 2013

  • Phase I study of GRN1005 in recurrent malignant glioma

    Clinical Cancer Research, 2013

  • Phase I/Ib Study of Lonafarnib and Temozolomide in Patients with Recurrent or Temozolomide Refractory Glioblastoma

    Cancer, 2013

  • The identification and characterization of breast cancer CTCs competent for brain metastasis

    Science Translational Medicine, 2013

  • Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosis

    Journal of Neuro-Oncology, 2013

  • Bevacizumab use in disseminated choroid plexus papilloma

    Journal of Neuro-Oncology, 2013

  • Case Studies of Patients Receiving Intraventricular Topotecan for Treatment of Neoplastic Meningitis

    Journal of Advanced Practice in Oncology, 2012

  • Phase I Pharmacologic and Pharmacodynamic Study of the Gamma Secretase (Notch) Inhibitor MK-0752 in Adult Patients with Advanced Solid Tumors

    Journal of Clinical Oncology, 2012

  • Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma

    Cancer, 2011

  • New Strategies in the Management of Leptomeningeal Metastases

    Archives of neurology, 2010

  • A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma

    Neuro-Oncology, 2010

  • Tonsillar Pseudotumor: Complications of Chronically-administered Temozolomide

    Journal of Neuro-Oncology, 2010

  • Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma

    Journal of Neuro-Oncology, 2010

  • A randomized trial on the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary brain tumor

    Journal of Neuro-Oncology, 2010

  • Comparative Risk of Leptomeningeal Dissemination of Cancer after Surgery or Stereotactic Radiosurgery for Supratentorial Solid Tumor Metastases

    Neurosurgery, 2009

  • Diagnostic tools for neoplastic meningitis: detecting disease, identifying patient risk, and determining benefit of treatment

    Seminars in Oncology, 2009

  • Two Phase II Trials of Temozolomide with Interferon-a2b (Pegylated and non-pegylated) in Patients with Recurrent Glioblastoma Multiforme

    British Journal of Cancer, 2009

  • Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma

    Journal of Neuro-Oncology, 2009

  • Comparative risk of leptomeningeal disease after resection or stereotactic radiosurgery for solid tumor metastasis to the posterior fossa

    Journal of Neurosurgery, 2008

  • Phase II Trial of Irinotecan and Thalidomide in Adults with Recurrent Glioblastoma Multiforme

    Neuro-Oncology, 2008

  • Low Grade Astrocytoma Presenting with Visual Loss

    Journal of Neuro-Oncology, 2008

  • Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma

    Journal of Neuro-Oncology, 2008

  • Prognostic Factors and Outcomes in Patients with Leptomeningeal Melanomatosis

    Neuro-Oncology, 2008

  • A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme

    Journal of Neuro-Oncology, 2007

  • Proteomic Identification of Biomarkers in the Cerebrospinal Fluid (CSF) of Astrocytoma

    Journal of Proteome Research, 2007

  • Synergistic effect and condition of pegylated interferon alpha with paclitaxel on glioblastoma

    International Journal of Oncology, 2006

  • Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study

    Clinical Cancer Research, 2006

  • Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: A relationship among efficacy, joint toxicity and anticonvulsant status

    Journal of Neuro-Oncology, 2006

  • Phase II Radiation Therapy Oncology Group trial of conventional radiation therapy followed by treatment with recombinant interferon-beta for supratentorial glioblastoma: results of RTOG 9710

    International Journal of Radiation Oncology, Biology, Physics, 2006

  • Combination celecoxib and temozolomide in C6 rat glioma orthotopic model

    Oncology Reports, 2006

  • Phase I Study of Capecitabine in Combination with Temozolomide in the Treatment of Patients with Brain Metastases From Breast Carcinoma

    Cancer, 2006

  • Neoplastic meningitis in patients with adenocarcinoma of the gastrointestinal tract

    Cancer, 2005

  • The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors

    Cancer, 2005

  • Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme

    Journal of Neuro-Oncology, 2005

  • Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: A North American brain tumor consortium study

    Journal of Clinical Oncology, 2005

  • Glutathione S-transferase polymorphisms and survival in primary malignant glioma

    Clinical Cancer Research, 2004

  • Response of neoplastic meningitis from solid tumors to oral capecitabine

    Journal of Neuro-Oncology, 2003

  • Paraneoplastic chorea: case study with autopsy confirmation

    Neuro-Oncology, 2002

  • Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme

    Journal of Clinical Oncology, 2002

  • Adenovirally-mediated transfer of E2F-1 potentiates chemosensitivity of human glioma cells to temozolomide and BCNU

    Int J Oncol, 2001

  • Peripheral nerve injury after brief lithotomy for transurethral collagen injection

    Urology, 2000

  • Radicular pain can be a symptom of elevated intracranial pressure

    Neurology, 1999

  • A phase II trial of high-dose bromodeoxyuridine with accelerated fractionation radiotherapy followed by procarbazine, lomustine, and vincristine for glioblastoma multiforme

    Int J Radiat Oncol Biol Phys, 1999

  • Papillary carcinoma of the thyroid: additional evidence in support of a familial component

    Cancer Invest, 1989